Search Results for: hold

20/20 GeneSystems Enters Engagement Agreement with ClearingBid, Pioneer of the First “Crowd-Powered” Open IPOs

Gaithersburg, MD – November 7, 2024 – 20/20 GeneSystems, Inc., an early market leader in multi-cancer early detection blood testing, announces that it has entered an Engagement Agreement with ClearingBid, Inc., a provider of the first platform enabling ordinary individuals and institutions to invest in IPOs at the same time, and on the same terms, […]

20/20 GeneSystems Enters Engagement Agreement with ClearingBid, Pioneer of the First “Crowd-Powered” Open IPOs Read More »

Our Team

Meet our Team Executive Management Jonathan Cohen President & CEO Mr. Cohen is the founder of our company and has served as Chief Executive Officer, President, and a director since its inception. He is a co-inventor of two of our most successful products, OneTest and BioCheck, and has led the commercial launch and sales of

Our Team Read More »

Company

Our Team Jonathan Cohen Founder, CEO Jonathan Cohen is the founder, president, and CEO of 20/20 GeneSystems. Under Mr. Cohen’s leadership, 20/20 has brought in approximately $7.5 million in grant funding and launched two successful products, a bio-detection kit for suspicious powders used by hundreds of emergency responder organizations worldwide and a blood test for

Company Read More »

Investing

Investing with 20/20 Investors Welcome! 20/20 GeneSystems is a U.S. based private corporation located in Maryland.  Investment opportunities are currently available and as a Reg A+ company, anyone can become a shareholder in our company. We have raised more than $5 million in equity crowd funding, making us one of the most successful crowd-funding life

Investing Read More »

Welcome to 20/20 GeneSytems

The Future of Cancer Screening 20/20 GeneSystems pioneers innovative bio-testing and cancer diagnostic tools that address compelling unmet needs. 20/20’s digital diagnostics business develops and commercializes A.I. powered cancer screenings tests deliver better tools to improve early detection of the most common cancers globally. Our emergency bio-detection business includes our patented BioCheck which is widely used by emergency responders.

Welcome to 20/20 GeneSytems Read More »